New Developments in Big, Open Access Data for Dementia
News Jun 19, 2014
This was aligned with the official launch of the MRC’s UK Dementias Research Platform (UKDP)announced by Secretary of State for Health, Jeremy Hunt, at the first Global Dementia Legacy Event held in London.
Imperial College London researchers are heavily involved in the UKDP big data initiative, which joins together ongoing studies across the UK to provide a research population approaching nearly 2 million people. They are also playing an important role in the largest of the contributing studies – the UK Biobank - which has recently started collecting imaging data on 100,000 participants, including scans of brains, hearts, bones and blood vessels.
Data from UK Biobank will be open access, allowing researchers from anywhere within the UK to tap into this vast resource. When possible, data from other studies in the UKDP will also will be made open access, promising a uniquely powerful way of enabling new discovery.
Dr Craig Ritchie from theDepartment of Medicine, Imperial College London who is on the UKDP steering committee said: “This really is a game changer in dementia research and will be a phenomenal resource to answer the big questions. It will enable the research community to move seamlessly between different levels of data, which simply could not happen if we worked in our own separate research groups and areas. By involving major players in the pharmaceutical and biotechnology industries, the platform will accelerate discovery of new treatments and interventions and allow the UK to take a leading role in the design and delivery of programmes to stop the progression of dementia.”
The UKDP is a public-private partnership that brings together top academic knowledge and cutting-edge technologies. The 22 studies that fall under its information umbrella will provide a research population approaching nearly 2 million people to evaluate dementia risk. Bringing this data together will allow researchers to scale up individual studies to explore their significance in larger populations, and also to drill down into more specific data that is only available in smaller samples. For example, if researchers want to investigate dietary links to dementia at a population level they can investigate the biologically possibility of this in a smaller study with specific genetic data.
Amongst the 22 studies are the Imperial College London CHARIOT project (Cognitive Health in Ageing Register: Investigational, Observational and Trial studies in dementia research) which is a register of over 20,000 elderly people and PREVENT which is an ambitious pilot project into mid-life to try to identify biological markers of the disease.
The UK Biobank will be the largest project under the new UKDP data umbrella. This was launched to collect a range of health data on 500,000 people. One of its several goals is to understand the course of Alzheimer’s over time. In May, the UK Biobank launched the world’s most ambitious research imaging programme that will collect brain, heart, blood vessel and bone scans from 100,000 participants. Scanning has begun in a single centre that is rapidly increasing its numbers, setting the ambitious goal of performing 18 full sets of scans and associated clinical examinations per day by September.
From the beginning of this ambitious project, researchers from Imperial College London have been involved in planning and translating the UK Biobank and its Imaging Enhancement from initial concept to current reality. Professor Paul Matthews Head of the Division of Brain Sciences in Department of Medicine at Imperial College London chairs the Imaging Working Group of the UK Biobank that initiated this recent addition to the observational studies. Several additional investigators from Imperial and other universities have developed the protocols for the different types of scan to ensure the data is correctly collected, stored and able to be shared.
“The Biobank promises to bring a new level of understanding to the risk of later life disease such as dementia,” says Professor Matthews. “It also shows the scientific community working together to address big challenges to answer important questions. No one will have special access to this rich dataset, although the many scientists volunteering their time to support the project are ensuring that it is truly ‘state of the art’. From the start, Imperial researchers have driven its development, moving it from a simple concept to the huge resource it will become in the near future. We are committed to this new scientific environment where open data creates a space for greater innovation and faster translation into treatment.”
Collaboration and knowledge-sharing is at the heart of these initiatives. Imperial College London is keen to open its doors further to this exciting new development in dementia research. It hosts the national Parkinson’s Disease Society brain bank and the MRC-NIHR National Phenome Centre, which helps provide a basis for evaluating the phenomes (combination of physical and personal traits) that are important in dementia. The recently launched Imperial Data Science Institute is also committed to exploring important questions around healthcare strategy and particularly dementia.
Consultant psychiatrist and Co-Director of the Neuroepidemiology and Ageing Research Department at Imperial College London, Dr Robert Perneczky said: “The UKDP and the UK Biobank will contribute significantly to developing treatments and interventions for dementia. We still don’t really understand the disease and this is why there are currently no viable treatments. By collecting and amassing data at a population level we can bridge this knowledge gap by tracing progression of the disease, identifying markers that can indicate onset, and discovering new treatments and interventions that can be applied as early as possible. By using big data and opening it up to innovation we can now start to take big steps towards preventing and halting dementia.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018